PepGen Inc.

NasdaqGS:PEPG Stock Report

Market Cap: US$114.1m

PepGen Management

Management criteria checks 2/4

PepGen's CEO is James McArthur, appointed in Jan 2021, has a tenure of 5.33 years. total yearly compensation is $3.32M, comprised of 18.7% salary and 81.3% bonuses, including company stock and options. directly owns 0.091% of the company’s shares, worth $104.11K. The average tenure of the management team and the board of directors is 1.1 years and 4.5 years respectively.

Key information

James McArthur

Chief executive officer

US$3.3m

Total compensation

CEO salary percentage18.66%
CEO tenure5.3yrs
CEO ownership0.09%
Management average tenure1.1yrs
Board average tenure4.5yrs

Recent management updates

Recent updates

Seeking Alpha • Mar 31

PepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some Relief

Summary PepGen Inc. shares plunged about 65% after mixed Phase 2 data for PGN-EDODM1 in DM1, with no functional improvement at 5 mg/kg. PGN-EDODM1 showed clean safety and biological activity, but efficacy was pretty modest and skewed by an outlier. So that higher 10 mg/kg dose is the next key catalyst. PEPG trades near cash value, reflecting heavy market skepticism on clinical success; the balance sheet supports operations through 2H26 and the next trial readout. I remain cautiously optimistic, awaiting 10 mg/kg data for clearer efficacy before considering new investment at these depressed levels. Read the full article on Seeking Alpha
Analysis Article • Nov 19

Is PepGen (NASDAQ:PEPG) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jun 27

Here's Why We're A Bit Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Mar 04

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Nov 19

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Aug 06

PepGen (NASDAQ:PEPG) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 31

PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments

Summary PepGen Inc. achieved positive data from the phase 2 CONNECT1 study, using PGN-EDO51 for the treatment of exon 51 skipping DMD patients; higher 10 mg/kg dosing of drug data is expected in early 2025. The global Duchenne Muscular Dystrophy treatment market size is expected to reach $8.19 billion in 2029. PGN-EDO53 is another EDO drug being developed by the company, with the goal of targeting 8% of DMD patients amenable to exon 53 skipping. Update on the use of PGN-EDODM1, in the ongoing phase 1 FREEDOM-DM1 study, expected in Q4 of 2024; Positive update could move the program towards a phase 2 trial. Read the full article on Seeking Alpha
Seeking Alpha • May 20

The Prognosis For PepGen

Summary PepGen's stock has experienced extreme volatility, with an 80% drop, a 370% rebound, and subsequent decline in 14 months. The rebound was driven by news that Sarepta's DMD exon 51 candidate had lower skipping output than PepGen's PGN-EDO51. PepGen is focused on developing oligonucleotide therapies for severe neuromuscular and neurologic diseases, with two programs in human trials. A full investment analysis around PepGen follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Jan 20

PepGen: Long Road Ahead

Summary PepGen is using exon skipping therapies to address muscular dystrophy conditions, specifically Duchenne muscular dystrophy (DMD) and Myotonic dystrophy type 1 (DM1). They are developing PGN-EDO51 and PGN-EDODM1. The market sizes for these therapies are estimated to be around $1.3 billion for DMD and potentially up to $4.5 billion for DM1, but there are financial and operational risks involved. Valuation doesn't offer enough of a margin of safety. Read the full article on Seeking Alpha
Analysis Article • Nov 13

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Jul 31

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 31

We Think PepGen (NASDAQ:PEPG) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Compensation Analysis

How has James McArthur's remuneration changed compared to PepGen's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$77m

Dec 31 2025US$3mUS$619k

-US$90m

Sep 30 2025n/an/a

-US$94m

Jun 30 2025n/an/a

-US$97m

Mar 31 2025n/an/a

-US$102m

Dec 31 2024US$4mUS$595k

-US$90m

Sep 30 2024n/an/a

-US$87m

Jun 30 2024n/an/a

-US$89m

Mar 31 2024n/an/a

-US$80m

Dec 31 2023US$3mUS$572k

-US$79m

Sep 30 2023n/an/a

-US$74m

Jun 30 2023n/an/a

-US$69m

Mar 31 2023n/an/a

-US$67m

Dec 31 2022US$5mUS$523k

-US$69m

Sep 30 2022n/an/a

-US$61m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$39m

Dec 31 2021US$4mUS$408k

-US$27m

Compensation vs Market: James's total compensation ($USD3.32M) is above average for companies of similar size in the US market ($USD627.70K).

Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.

CEO

James McArthur (63 yo)

5.3yrs
Tenure
US$3,316,783
Compensation

Dr. James G. McArthur, Ph D., serves as the President, Chief Executive Officer, Treasurer and Secretary of PepGen Inc. since January 21, 2021. He joined PepGen Inc. in January 2021.He serves as the Presid...

Leadership Team

NamePositionTenureCompensationOwnership
James McArthur
President5.3yrsUS$3.32m0.091%
$ 104.1k
Noel Donnelly
Chief Financial Officer4.6yrsUS$1.76m0.025%
$ 28.6k
Joseph Vittiglio
Chief Business & Legal Officer and Secretaryless than a yearUS$1.32mno data
Kasra Kasraian
Chief Technical Officer1yrno data0%
$ 0
Emiko Bryant
Senior Vice President of HR & Administration1.2yrsno datano data
Hayley Parker
Senior Vice President of Global Regulatory Affairs & Quality1.9yrsno datano data
Paul Streck
Executive VP and Head of Research & Development1.8yrsUS$2.07m0.016%
$ 18.7k
Pallavi Lonkar
Vice President & Head of Preclinicalless than a yearno datano data
Gregory Song
Executive Director & Head of Biometricsless than a yearno datano data
Melissa Michaels
Executive Director & Head of Regulatory Affairs CMCless than a yearno datano data
1.1yrs
Average Tenure
58yo
Average Age

Experienced Management: PEPG's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
James McArthur
President5.3yrsUS$3.32m0.091%
$ 104.1k
Laurie Keating
Independent Chair of the Board4.4yrsUS$102.40k0.0060%
$ 6.9k
Arthur Krieg
Scientific Advisory Board Memberno datano datano data
Mitchell Finer
Independent Non-Executive Director1.2yrsUS$64.51k0%
$ 0
Heidi Henson
Independent Director4.8yrsUS$78.40k0%
$ 0
Joshua Resnick
Independent Director5.5yrsUS$64.40k0%
$ 0
Howard Mayer
Independent Director2.5yrsUS$70.90k0%
$ 0
Habib Dable
Independent Director3.7yrsUS$71.90k0%
$ 0
Elizabeth McNally
Scientific Advisory Board Memberno datano datano data
Matthew Wood
Scientific Advisory Board Memberno dataUS$85.25kno data
Charles Thornton
Scientific Advisory Board Memberno datano datano data
John Day
Scientific Advisory Board Member4.6yrsno datano data
4.5yrs
Average Tenure
63yo
Average Age

Experienced Board: PEPG's board of directors are considered experienced (4.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/15 09:11
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PepGen Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Debjit ChattopadhyayGuggenheim Securities, LLC
Ananda GhoshH.C. Wainwright & Co.